A host of China stocks are recommended by investment analysts whether or not the economy gets a boost from measures taken this week to boost the sluggish domestic economy there. On Tuesday, the People's Bank of China announced a series of steps designed to lift the country's slumping economy. Policies introduced by the central bank included slashing its reserve requirement ratio — the amount of cash banks need to hold — to boost lending, and cutting other corporate and household rates, including existing mortgages.
Stocks in China rose in response, with the CSI 300 Index climbing 4.3% Tuesday, its best day since July 2020. Hong Kong's Hang Seng Index also climbed more than 4% Tuesday.
But whether or not the latest policy steps succeed, CNBC Pro screened for China stocks that analysts praise regardless of the pace of economic growth at home. We screened for stocks meeting the following criteria: Member of the SPDR S & P China ETF , which tracks publicly traded companies domiciled in China available to foreign investors Market capitalization of at least $1.5 billion Covered by at least eight analysts Buy ratings from at least 55% of those analysts Upside to average price target of at least 20% Shares of biopharmaceutical firm Structure Therapeutics are up about 4% this year.
The company's lead pipeline asset, GSBR-1290, is an oral GLP-1 treatment similar to diabetes and weight loss drugs such as Ozempic and Wegovy. Structure Therapeutics currently has a market capitalizatio.
